BRD0209

Overview

BRD0209 is a potent, selective and dual inhibitor of GSK3α/β inhibitor (GSK3α IC 50 = 19 nM; GSK3β IC 50 = 5 nM). BRD0209 is also a reversible ATP-competitive inhibitor with fast-off kinetics ( K i = 4.2 nM, respectively). BRD0209 is a tricyclic pyrazolotetrahydroquinolinone compound. BRD0209 has the potential for the research of mood disorder diseases.

Application

Products | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Depression | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > GSK-3

Product Information

• Catalog No.: HY-117822
• CAS No.: 1597439-87-6
• Molecular Formula: C22H25N3O
• Molecular Weight: 347.45
• Purity: 99.63%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (5.99 mM); Clear solution
• Availability: In-stock

Source

Original product source